Conduit Pharmaceuticals INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
S-1/A: Conduit Pharmaceuticals Secures Exclusive License from AstraZeneca in Multi-Million Dollar Deal
Conduit Pharmaceuticals enters into a licensing agreement with AstraZeneca, gaining exclusive rights to develop and commercialize certain pharmaceutical compounds in exchange for upfront payments, equity issuance, and future revenue sharing.
NASDAQ
Conduit Pharmaceuticals files an S-1 registration statement for the resale of up to 22,004,465 shares of common stock issued to AstraZeneca and Nirland Limited.